Last reviewed · How we verify
NCT05595070: RadboudStem
Oral Complications After Haematopoietic Stem Cell Transplantation: a Retrospective Study
trial testing Haematopoietic stem cell transplantation in Stem Cell Transplant Complications in 200 participants. Status unknown.
31 December 2023
Quick facts
| Lead sponsor | Radboud University Medical Center |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 1 April 2022 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- Haematopoietic stem cell transplantation
Conditions studied
- Stem Cell Transplant Complications — all drugs for Stem Cell Transplant Complications →
- Oral Complication — all drugs for Oral Complication →
Sponsor
Radboud University Medical Center
Who can join
18 and older, any sex, with Stem Cell Transplant Complications or Oral Complication. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Haematopoietic stem cell transplantation (HSCT) is a potentially lifesaving treatment option for various diseases. It involves infusion of stem cells after a conditioning regimen of chemotherapy with or without total body irradiation. There is a concern that HSCT and accompanying treatments may increase the risk for oral complications. Nevertheless, longitudinal studies measuring oral health before and after HSCT are scarce. Hence, we formulated the following research question: In adult HSCT recipients, do oral health parameters change from baseline (pre-HSCT) to 3 - 24 months post-HSCT, and is the type of conditioning regimen associated with this change in oral health parameters? To answer this research question, we will use data from the electronic health records of the Radboudumc (Epic and Dentium). We will include at least seventy-five adult patients who are examined both before and after HSCT at the department of Dentistry (Radboudumc) as part of an oral care program. The following oral health parameters were assessed: status praesens, pocket probing depth, bleeding on probing, periodontal epithelial surface area, periodontal inflamed surface area, xerostomia, unstimulated and stimulated salivary flow rate and pH, cariesactivity, oral chronic Graft-versus-Host Disease and dental treatments. Patients were subjected to different regimens in preparation for HSCT, namely myeloablative, reduced intensity or non-myeloablative conditioning. To estimate the association between conditioning regimen and the change in oral health parameters, we will use mixed effects models with random effects, adjusted for potential confounders. Results will be reported as regression coefficients with corresponding 95% confidence intervals.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Periodontal changes after haematopoietic cell transplantation and the role of conditioning regimen intensity.
van Gennip LLA, Bulthuis MS, Hannink G, Bronkhorst EM, et al · · 2025 · PMID 40548989 · DOI 10.1007/s00520-025-09654-9
Verify or expand the search:
- PubMed search for NCT05595070
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Stem Cell Transplant Complications
Currently open trials in the same condition.
- NCT07509749 — Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease) · Phase 2 · recruiting
- NCT07340723 — Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease ) · Phase 2 · recruiting
- NCT06541002 — A Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors · NA · recruiting
- NCT05421416 — Loratadine for the Prevention of G-CSF-related Bone Pain · Phase 2 · recruiting
- NCT06512545 — Modified Second Haplo-transplantation for Graft Failure · NA · recruiting
Other Radboud University Medical Center trials
Trials by the same sponsor.
- NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
- NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
- NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
- NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
- NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05595070 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
- Last refreshed: 26 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05595070.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing